WELKOM,   Inloggen   |   Registreren Beursnieuws via RSS
Grafiek Oxurion (ex ThromboGenics)Oxurion (ex ThromboGenics)

BRU: OXUR | BE0003846632
Euronext Brussel
2,035 EUR   (0,74%)
26 november 2021

Kosten order 3.000 EUR: 2,90 EUR
Beleg goedkoper met DEGIRO Begin direct met beleggen bij DEGIRO* »
* Met beleggen kunt u uw inleg verliezen

Vandaag

1,950

2,055

12 maanden

1,704

2,975

Beleg goedkoper met DEGIRO
Kosten order 3.000 EUR: 2,90 EUR
Samenvatting Analisten Nieuws Agenda Insiders Grafiek Koersen

Laatste nieuws over Oxurion

Nieuws via RSS voor Oxurion (ex ThromboGenics)

OXURION to Present at the Ophthalmology Day at BTIG

24 november 2021 - 07:30  |  Oxurion NV
Leuven, BELGIUM, Boston, MA, US - November 24, 2021 – 07.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, today...
Trivano.com »

OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures

22 november 2021 - 07:00  |  Oxurion NV
 Provides Additional Capital to further Develop the Company’s Innovative Pipeline of Novel Clinical Assets, THR-687 and THR-149 Leuven, BE, Boston, MA, US – November 22, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...
Trivano.com »

OXURION NV - First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME)

15 november 2021 - 07:00  |  Oxurion NV
THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly 50% of the patient population suboptimally responding to anti-VEGF therapy Leuven, BE, Boston, MA, US – 15 November 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a...
Trivano.com »

Oxurion NV Announces Initiation of Equity Analyst Coverage by H.C. Wainwright with a “Buy” Recommendation

04 november 2021 - 07:00  |  Oxurion NV
Leuven, BE, Boston, MA, US – November 4, 2021 – 07.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announces...
Trivano.com »

Sofina uitblinker in groene Bel20

14 oktober 2021 - 18:21  |  Tijd.be
De Europese beurzen schudden toegenomen inflatiezorgen van zich af en sloten op het hoogste peil in twee weken. Umicore kreeg een lauwe nieuwe volger. MDxHealth werd beloond voor zijn Amerikaanse beur...
Tijd.be »

Oxurion NV Announces First Patient Dosed in its Phase 2 Study Evaluating THR-687 for the treatment of Diabetic Macular Edema (DME)

13 oktober 2021 - 07:00  |  Oxurion NV

OXURION - Positive Phase 2 Part A THR-149 data shared at the America Society of Retinal Specialists (ASRS) Annual Scientific Meeting

11 oktober 2021 - 07:00  |  Oxurion NV

Euronext Brussel: Colruyt in promotie, Oxurion ziet licht

30 september 2021 - 12:45  |  Tijd.be

Positieve testresultaten voor oogmiddel Oxurion

30 september 2021 - 12:20  |  Bolero.be

OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

30 september 2021 - 07:00  |  Oxurion NV

14 jobs sneuvelen bij reorganisatie biotechbedrijf Oxurion

09 september 2021 - 19:59  |  Tijd.be

Oxurion NV Business & Financial Update – H1 2021

09 september 2021 - 19:00  |  Oxurion NV

Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal

17 augustus 2021 - 08:00  |  Oxurion NV

Oxurion NV - Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD profiles of THR-687 and THR-149

16 augustus 2021 - 08:00  |  Oxurion NV

OXURION to Participate in Upcoming Investor Meetings

05 augustus 2021 - 17:45  |  Oxurion NV

Oudere nieuwsberichten »